The Cloud's Silver Lining: Beyond Tonix's Missed Phase 2 Primary Endpoint For Fibromyalgia
- TNX-102SL missed its primary endpoint: After 12 weeks, the average decrease in pain was not statistically significant.
- Yet, over the 12 weeks, compared to those who took the placebo, there was a greater decrease in average pain score for those taking TNX-102SL.
- More important, compared to the control group, the proportion of patients whose pain score declined at least 30% was statistically significant.
- There were other statistically results, including better scores in sleep quality and in two key variables that assess Fibromyalgia improvement comprehensively.
- The FDA is likely to approve TNX-102SL for both Fibromyalgia and PTSD, which is a bigger market.